Zhongzhi Pharmaceutical Holdings Ltd. made a $3 million investment in a series A financing round of stem cell therapy developer Gabaeron Inc. Dec. 21, expected to help propel Gabaeron’s preclinical Alzheimer’s disease (AD) candidate into phase I testing. Read More
In a recently published study, researchers based at Université Paris-Saclay identified OXA-1186, a novel carbapenemase related to the previously known OXA-198 enzyme, in a clinical isolate of Citrobacter freundii. This discovery underscores the ongoing challenge of antibiotic resistance in bacterial pathogens. Read More
Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint research on mRNA vaccine and treatment development. Read More
A recent study by scientists at Tongji University highlights the potential of TBAJ-587, a novel diarylquinoline, in addressing the challenge of treating Mycobacterium abscessus infections, a subset of nontuberculous mycobacteria that exhibit resistance to many antibiotics. Read More
Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely unexplored due to its rapid progression and a scarcity of surgical specimens. Read More
Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of poly(ADP-ribose) polymerase (PARP) inhibitors, are only effective in 5% to 7% of patients. Investigators at the Third People’s Hospital of Chengdu and collaborators described the synergistic effect obtained by the combined administration of LB-23, a PARP1 degrader, and JQ1, a BRD4 inhibitor, in homologous recombination (HR)-proficient pancreatic cancer models. Read More
The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV infections are urgently needed. Read More
Scientists at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed pyridazinopyridone derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors. As such, they are reported to be useful for the treatment of cancer, gingival fibromatosis, cardiofaciocutaneous and Noonan syndromes. Read More
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a target protein binding moiety through a linker reported to be useful for the treatment of cancer, dermatological, neurological, respiratory and cardiovascular disorders, autoimmune diseases, infections and transplant rejection, among others. Read More
Caseinolytic protease P (ClpP) is a conserved serine protease present in both bacteria and humans, essential for maintaining protein quality by degrading misfolded proteins. Read More
Researchers at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified aromatic amide derivatives acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer. Read More
Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related to cytokine release syndrome and limited efficacy. Read More
Scientists at Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have described GTPase KRAS and/or its mutant inhibitors reported to be useful for the treatment of cancer. Read More
